Total Payments
$1,900
2024 Payments
$1,520
Companies
4
Transactions
16
Medicare Patients
1,281
Medicare Billing
$63,452
Payment Breakdown by Category
Research$1,435 (75.5%)
Food & Beverage$379.14 (20.0%)
Education$85.47 (4.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,435 | 11 | 75.5% |
| Food and Beverage | $379.14 | 4 | 20.0% |
| Education | $85.47 | 1 | 4.5% |
Payments by Type
Research
$1,435
11 transactions
General
$464.61
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,435 | 11 | $0 (2024) |
| Lilly USA, LLC | $197.84 | 2 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $182.27 | 2 | $0 (2024) |
| Biofrontera Inc. | $84.50 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,520 | 12 | ABBVIE INC. ($1,435) |
| 2023 | $208.72 | 2 | Lilly USA, LLC ($124.22) |
| 2022 | $170.42 | 2 | Regeneron Healthcare Solutions, Inc. ($96.80) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/10/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $545.29 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ||||||
| 11/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $40.00 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ||||||
| 11/10/2024 | ABBVIE INC. | — | — | In-kind items and services | $38.86 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $249.66 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $49.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $34.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $249.66 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $126.58 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 08/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Education | In-kind items and services | $85.47 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/10/2023 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | Cash or cash equivalent | $124.22 | General |
| Category: Immunology | ||||||
| 06/06/2023 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $84.50 | General |
| Category: DERMATOLOGY | ||||||
| 10/25/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $96.80 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/31/2022 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $73.62 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ABBVIE INC. | $1,435 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 373 | 498 | $73,202 | $19,876 |
| 2022 | 11 | 363 | 497 | $66,376 | $17,579 |
| 2021 | 9 | 335 | 598 | $63,412 | $17,265 |
| 2020 | 8 | 210 | 337 | $34,759 | $8,732 |
Total Patients
1,281
Total Services
1,930
Medicare Billing
$63,452
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 45 | 45 | $13,140 | $3,582 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 48 | $9,264 | $3,458 | 37.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 51 | 60 | $14,280 | $2,961 | 20.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 31 | 36 | $8,424 | $2,296 | 27.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 59 | 69 | $8,763 | $1,958 | 22.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 34 | $4,692 | $1,781 | 37.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 34 | 45 | $4,140 | $1,394 | 33.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 30 | 30 | $4,140 | $1,063 | 25.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $3,895 | $976.00 | 25.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 34 | 112 | $2,464 | $407.67 | 16.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 61 | 68 | $16,184 | $3,457 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 63 | 72 | $9,936 | $3,278 | 33.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 31 | 37 | $8,658 | $2,357 | 27.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 54 | 66 | $8,382 | $2,036 | 24.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 25 | 25 | $5,125 | $1,325 | 25.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 34 | 40 | $3,680 | $1,217 | 33.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $3,796 | $1,095 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 15 | $2,895 | $1,094 | 37.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 17 | 23 | $2,944 | $729.68 | 24.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 15 | 15 | $2,070 | $514.90 | 24.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 37 | 123 | $2,706 | $474.69 | 17.5% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 70 | 82 | $19,516 | $4,730 | 24.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 60 | $8,226 | $2,994 | 36.4% |
| 17000 | Destruction of skin growth | Office | 2021 | 59 | 75 | $9,525 | $2,250 | 23.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 32 | 32 | $6,560 | $2,140 | 32.6% |
About Bryan Dooley
Bryan Dooley is a Physician Assistant healthcare provider based in Beavercreek, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2019. The National Provider Identifier (NPI) number assigned to this provider is 1346707379.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Bryan Dooley has received a total of $1,900 in payments from pharmaceutical and medical device companies, with $1,520 received in 2024. These payments were reported across 16 transactions from 4 companies. The most common payment nature is "" ($1,435).
As a Medicare-enrolled provider, Dooley has provided services to 1,281 Medicare beneficiaries, totaling 1,930 services with total Medicare billing of $63,452. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Beavercreek, OH
- Active Since 02/26/2019
- Last Updated 02/26/2019
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1346707379
Products in Payments
- RINVOQ (Biological) $1,306
- DUPIXENT (Biological) $182.27
- OLUMIANT (Drug) $124.22
- AMELUZ (Drug) $84.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Beavercreek
Alexandra Wilson, Pa-C, PA-C
Physician Assistant — Payments: $1,031
Physician Assistant $1,031
Michelle Ortman, P.a.-C, P.A.-C
Physician Assistant — Payments: $1,022
Physician Assistant $1,022
Laura Minik, Pa-C, PA-C
Physician Assistant — Payments: $947.01
Physician Assistant $947.01
Mrs. Jennifer Gonzalez, Pa, PA
Physician Assistant — Payments: $701.61
Physician Assistant $701.61
Kelly Bultman
Physician Assistant — Payments: $497.93
Physician Assistant $497.93
Elizabeth Gleason, Pa, PA
Physician Assistant — Payments: $401.65
Physician Assistant $401.65